Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?

Area of Science:

• Oncology
• Molecular Biology
• Nephrology

Background:

• The Hippo pathway is crucial in cancer development and resistance to targeted therapies.
• TEAD inhibitors are emerging as a promising class of anticancer drugs, with several in clinical trials.
• Understanding the Hippo pathway's role in kidney development is essential for assessing potential toxicities.

Purpose of the Study:

• To review the involvement of the Hippo pathway in various cancers.
• To discuss the therapeutic potential of TEAD inhibitors in oncology.
• To evaluate the safety profile of Hippo pathway inhibition, focusing on renal effects, and to guide clinical translation.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the Hippo pathway's role in cancer pathogenesis and drug resistance.
• Examination of the Hippo pathway's function in kidney development and homeostasis.

Main Results:

• The Hippo pathway regulates cell proliferation, survival, and tissue growth, making it a key target in cancer.
• TEAD inhibitors have demonstrated efficacy in preclinical cancer models.
• Preliminary data suggest potential renal side effects associated with Hippo pathway inhibition, necessitating careful evaluation.

Conclusions:

• TEAD inhibitors represent a significant advancement in cancer therapy.
• Further research is required to fully understand and mitigate the potential kidney-related toxicities of Hippo pathway-targeted drugs.
• Optimizing therapeutic strategies is crucial for maximizing patient benefit and ensuring the long-term safety of these novel agents.